Objective To evaluate the risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA)
patients receiving tofacitinib versus those receiving tumor necrosis factor (TNF) inhibitors …

Objective To evaluate the risk of venous thromboembolism (VTE) with tofacitinib compared
with TNFis in patients with RA. Methods RA patients initiating tofacitinib or a TNFi without …

Objective. The ORAL Surveillance trial found a dose-dependent increase in venous
thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor …

Objective In the ORAL (Oral Rheumatoid Arthritis triaL) Surveillance study of patients with
rheumatoid arthritis aged≥ 50 years with≥ 1 additional cardiovascular risk factor, incidence …

Objectives Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis …

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib
versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with …

Background: In patients with rheumatoid arthritis (RA), persistent inflammation and
increasing disease activity are associated with increased risk of adverse events (AEs) …

Background Increases in lipid levels and cancers with tofacitinib prompted a trial of major
adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis …

Objectives Recent results from 'ORAL Surveillance'trial have raised concerns regarding the
cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA). We further …

Objectives To evaluate malignancies and their associations with baseline risk factors and
cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in …